Skip to main content
Premium Trial:

Request an Annual Quote

NeuMoDx Gets FDA Emergency Use Authorization for Coronavirus Test

NEW YORK – NeuMoDx received Emergency Use Authorization from the US Food and Drug Administration on Monday for a COVID-19 assay on its fully automated, mid- and high-throughput diagnostics systems, according to a document posted on the agency's website.

Called the NeuMoDx SARS-CoV-2 Test Strip, the assay was authorized for the NeuMoDx 288 Molecular and NeuMoDx 96 molecular systems. It detects SARS-CoV-2 in nasal, nasopharyngeal, and oropharyngeal swab samples from patients suspected of having COVID-19, the disease caused by SARS-CoV-2 infection. The mulitplexed test detects the Nsp2 gene and the N gene of the virus, and the time to first results on the instrument is approximately 80 minutes 

The NeuMoDx systems are continuous, random-access analyzers that incorporate a proprietary dried reagent format, magnetic particle affinity capture, and real-time PCR, in a multi-sample microfluidic cartridge-based system. 

In 2018, NeuMoDx entered a partnership and milestone-based merger agreement with Qiagen, a firm that Thermo Fisher Scientific now plans to acquire. Qiagen also received EUA on Monday for its QIAstat-Dx Respiratory SARS-CoV-2 Panel.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.